BPC-157 dosage calculator: what the research actually shows. | Reddit

Why is there no legitimate BPC-157 dosage calculator for humans?

Dosage calculators are useful tools in pharmacology when two conditions are met: there is established human pharmacokinetic data (how the drug moves through the body), and there are controlled trial results that define a therapeutic window. BPC-157 meets neither condition for human use.

Every BPC-157 dosage calculator you will find online performs the same operation: it takes a rodent dose from a published study, applies a body-surface-area conversion factor (often the Reagan-Kelly equation from FDA preclinical guidance), and outputs a suggested human dose. This approach is used in early-phase drug development as a rough first estimate before Phase I safety trials, not as a clinical dosing protocol.

Applying that estimate as though it were a validated human dose is like reading a runway approach checklist before ever having flown the plane. The logic follows, but the system hasn’t been tested in the thing that matters.

What does the preclinical dosing research actually show?

The preclinical literature on BPC-157 spans hundreds of rodent studies and covers a wide range of dose levels, administration routes, and tissue targets. Here is an honest summary of what that research shows, without translating it into a human dosing recommendation.

Dose range tested in animals

Studies have administered BPC-157 to rodents at doses ranging from approximately 1 microgram per kilogram (mcg/kg) to 10 mcg/kg of body weight, with some studies using higher doses to assess tolerability. These doses were administered subcutaneously, intraperitoneally, and orally. Researchers have generally reported a wide tolerability window in animal models, with no significant acute toxicity observed at experimental doses.

A small number of studies have also explored oral administration, noting that BPC-157 appears to retain activity when given by mouth in animal models, which is unusual for peptides that are typically degraded in the gastrointestinal tract. The proposed mechanism involves BPC-157’s structural stability, given its origin as a fragment of a gastric protein.

Why can’t animal doses be used as human doses?

Body-weight scaling between species is not a one-to-one conversion. Rodents have substantially higher metabolic rates per unit of body weight than humans, which affects drug clearance, distribution, and concentration at the target tissue. A 1 mcg/kg dose in a 200-gram rat does not produce the same systemic exposure as a 1 mcg/kg dose in a 70-kilogram human.

Beyond pharmacokinetics, there are no human data on BPC-157’s bioavailability by any route, its plasma half-life in humans, its tissue distribution in humans, or its dose-response relationship in any human population. These are the inputs any legitimate dosage calculator would require.

What are online dosing charts actually doing?

Most BPC-157 dosing guides circulating in peptide communities suggest ranges like 200–500 micrograms per day (often written as 200–500 mcg), administered subcutaneously once or twice daily. These figures trace back to a handful of rodent studies, scaled to human body weight and rounded.

The communities sharing these numbers are often well-intentioned and sometimes include individuals with genuine scientific literacy. That doesn’t change what the numbers are: unvalidated estimates derived from animal data, circulated peer-to-peer without clinical oversight, pharmacovigilance, or adverse event reporting.

The practical risks of following such a chart include:

• Unknown purity of the source compound. BPC-157 cannot be legally obtained through licensed compounding pharmacies in the U.S. Products available through gray-market channels are not manufactured under USP pharmaceutical standards and carry real contamination risk.
• No adverse event monitoring. Self-administration without clinical oversight means no one is tracking unexpected responses or potential harms.
• No interaction screening. The potential for BPC-157 to interact with other medications or peptides has not been studied in humans.
• Dose inaccuracy. Correctly measuring doses in the microgram range requires pharmaceutical-grade equipment. Small errors produce large relative dose variations.

Why is there no established dose for BPC-157?

BPC-157 is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List, so no regulator has evaluated a dose for safety or efficacy. This is not a judgment about whether the compound is interesting scientifically; it reflects the FDA’s view that the current evidence base has not yet supported placement on that list.

That status is in active transition. On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee met to review BPC-157 for addition to the 503A Bulks List. Any recommendation from that committee is non-binding, and FDA has not issued a final determination. Whether any therapy is appropriate for you is a clinical decision, so the right next step is a conversation with a licensed clinician rather than a dosing chart.

What is actually available through clinician supervision?

People researching BPC-157 dosing are often looking to support connective tissue recovery, gut health, or general repair and recovery goals. These objectives can be addressed through clinician-supervised programs using peptides with established compounding pathways.

Sermorelin is a Category 1 peptide that supports natural growth hormone release and is available through licensed 503A compounding pharmacies with a clinician’s prescription. Compounded in the USA by licensed 503A pharmacies with no hidden overseas supply chain, Sermorelin is part of a legitimate, supervised recovery and body composition framework.

PepScribe’s Recovery & Repair program routes patients to clinician evaluation for exactly these goals, with the clinician determining which currently available, legally compoundable peptides are appropriate for the individual patient.

Frequently asked questions